The true burden and risk of cholera: implications for prevention and control

被引:161
作者
Zuckerman, Jane N.
Rombo, Lars
Fisch, Alain
机构
[1] UCL Royal Free & Univ Coll Med Sch, WHO, Collaborating Ctr Travel Med, Acad Ctr Travel Med & Vaccines, London NW3 2PF, England
[2] Karolinska Inst, S-10401 Stockholm, Sweden
[3] Ctr Hosp Villeneuve, Int Ctr Vaccinat & Emergency Trop Med, St Georges, France
关键词
D O I
10.1016/S1473-3099(07)70138-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Cholera is a substantial health burden on the developing world and is endemic in Africa, Asia, South America, and Central America. The exact scale of the problem is uncertain because of limitations in existing surveillance systems, differences in reporting procedures, and failure to report cholera to WHO; official figures are likely to greatly underestimate the true prevalence of the disease. We have identified, through extensive literature searches, additional outbreaks of cholera to those reported to WHO, many of which originated from the Indian subcontinent and southeast Asia. Such underestimation of cholera can have important implications for decisions on provision of health interventions for indigenous populations, and on risk assessments for travellers. Furthermore, until recently, it has not been possible to implement public-health interventions in low-income countries to eliminate disease, and the prevention of cholera in travellers has been limited to restrictive guidelines. However, a vaccine against cholera is now available that has proven efficacy and tolerability in mass vaccination campaigns in low-income countries, and among travellers.
引用
收藏
页码:521 / 530
页数:10
相关论文
共 106 条
  • [1] Vaccines against cholera, typhoid fever and shigellosis for developing countries
    Acosta, CJ
    Galindo, CM
    Deen, JL
    Ochiai, RL
    Lee, HJ
    von Seidlein, L
    Carbis, R
    Clemens, JD
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (12) : 1939 - 1951
  • [2] The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance
    Agtini, MD
    Soeharno, R
    Lesmana, M
    Punjabi, NH
    Simanjuntak, C
    Wangsasaputra, F
    Nurdin, D
    Pulungsih, SP
    Rofiq, A
    Santoso, H
    Pujarwoto, H
    Sjahrurachman, A
    Sudarmono, P
    von Seidlein, L
    Deen, JL
    Ali, M
    Lee, H
    Kim, DR
    Han, OP
    Park, JK
    Ingerani, AS
    Oyofo, BA
    Campbell, JR
    Beecham, HJ
    Corwin, AL
    Clemens, JD
    [J]. BMC INFECTIOUS DISEASES, 2005, 5 (1)
  • [3] Traveller's diarrhoea
    Al-Abri, SS
    Beeching, NJ
    Nye, FJ
    [J]. LANCET INFECTIOUS DISEASES, 2005, 5 (06) : 349 - 360
  • [4] Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis
    Ali, M
    Emch, M
    von Seidlein, L
    Yunus, M
    Sack, DA
    Rao, M
    Holmgren, J
    Clemens, JD
    [J]. LANCET, 2005, 366 (9479) : 44 - 49
  • [5] Risk assessment and disease prevention in travelers visiting friends and relatives
    Angell, SY
    Behrens, RH
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2005, 19 (01) : 49 - +
  • [6] [Anonymous], 1995, Wkly Epidemiol Rec, V70, P201
  • [7] [Anonymous], 2006, Weekly epidemiological record
  • [8] Travel medicine considerations for North American immigrants visiting friends and relatives
    Bacaner, N
    Stauffer, B
    Boulware, DR
    Walker, PF
    Keystone, JS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (23): : 2856 - 2864
  • [9] Can oral cholera vaccination play a role in controlling a cholera outbreak?
    Calain, P
    Chaine, JP
    Johnson, E
    Hawley, ML
    O'Leary, MJ
    Oshitani, H
    Chaignat, CL
    [J]. VACCINE, 2004, 22 (19) : 2444 - 2451
  • [10] *CDC, 2004, CHOLERA OTHER VIBRIO